Prof. Ros Eeles, Author at Grand Rounds in Urology

Prof. Ros Eeles

Royal Marsden Hospital, University of London

London, England

Professor Rosalind (Ros) Eeles is a clinician as well as a scientist, running both a laboratory at The Institute of Cancer Research, London, and a Cancer Genetics and Uro-Oncology Clinic at the ICR’s partner hospital, The Royal Marsden NHS Foundation Trust. She trained at The University of Cambridge and St Thomas’ Hospital Medical School. After completing her higher medical training, Professor Eeles trained in Clinical Oncology at The Royal Marsden and then in cancer genetics with Professor Bruce Ponder. She then spent a year as an Assistant Professor at the University of Utah in Salt Lake City, United States, where she studied hereditary prostate cancer, worked in research in cancer genetics and had oncology clinical experience. She has sat on several genetics advisory committees, both national and international, including the Department of Health Genetics Advisory Committee, has given evidence to the House of Lords’ Select Committee on genomic medicine and edited a special edition of the Familial Cancer journal on delivering cancer genetics services. She is now a Professor of Oncogenetics at The ICR and an Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden NHS Foundation Trust.

Disclosures:

Talks by Prof. Ros Eeles

Update on IMPACT – Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and Men with Lynch Syndrome

Posted by Prof. Ros Eeles | Jan 2024

Ros Eeles, PhD, FRCP, FRCR, describes interim results from the IMPACT study, showing a recommendation for yearly PSA screening in BRCA2 mutation carriers. Those with gene mutations are more likely to have aggressive disease, almost twice as much as those without. In BRCA2 carriers, positive predictive value of biopsy and PSA was significantly higher, with a younger onset of mutations and higher Gleason scores.

Professor Eeles turns to a small recruitment study of the Lynch Cohort, which showed 85% of MSH2 carriers and 75% of MSH6 carriers had clinically significant disease, while MSH2 and MSH6 non-carriers had no clinically significant disease. The participants had a mean age 52.8 and 81% of participants do not have a strong family history of prostate cancer. As it is still unknown if very early disease could be managed by active surveillance, Professor Eeles suggests data is still needed to support active surveillance and MRI for early-stage disease in these carriers.

Prof. Ros Eeles

Royal Marsden Hospital, University of London

London, England

Talks by Prof. Ros Eeles

Update on IMPACT – Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and Men with Lynch Syndrome

Join the GRU Community

You have Successfully Subscribed!